BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026Business Wire · 1 day ago
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal CancerBusiness Wire · 2 days ago
BeOne Medicines: Brukinsa And Tevimbra Face A High BarSeeking Alpha · 2 days ago
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5Business Wire · 3 days ago
Oncolytics Biotech (TSE:ONC) Share Price Breaks Above Two Hundred Day Moving Average – Should You Sell?Defense World · 3 days ago
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026Business Wire · 6 days agoBeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $1.63 | $2.05 | Beat |
| May 6, 2026 | $0.73 | $1.96 | Beat |
| Feb 26, 2026 | $1.60 | $0.58 | Miss |
| Nov 6, 2025 | $0.72 | $1.09 | Beat |
| Aug 6, 2025 | $0.48 | $0.84 | Beat |
| May 7, 2025 | -$0.71 | $1.22 | Beat |